MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA MeetingBusiness Wire • 12/05/22
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in JapanBusiness Wire • 11/18/22
MEI Pharma Reports First Quarter Fiscal Year 2023 Results and Operational HighlightsBusiness Wire • 11/14/22
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022Business Wire • 11/03/22
MEI Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022Business Wire • 09/06/22
MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022Business Wire • 09/01/22
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell MalignancyBusiness Wire • 07/18/22
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People OfficerBusiness Wire • 06/22/22
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid CongressBusiness Wire • 06/10/22
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022Business Wire • 06/04/22
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022Business Wire • 05/26/22
MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational HighlightsBusiness Wire • 05/23/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 05/19/22
MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 05/19/22
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 05/18/22